Exceptional Response of

Proto-Oncogene Proteins B-raf / genetics Humans Protein Kinase Inhibitors / therapeutic use Mutation Male Female Middle Aged Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors

Journal

JCO precision oncology
ISSN: 2473-4284
Titre abrégé: JCO Precis Oncol
Pays: United States
ID NLM: 101705370

Informations de publication

Date de publication:
May 2024
Historique:
medline: 31 5 2024
pubmed: 31 5 2024
entrez: 31 5 2024
Statut: ppublish

Résumé

Complete remission of BRAF V600E-driven ACC CUP by BRAF/MEK inhibition underscores importance of precision oncology.

Identifiants

DOI: 10.1200/PO.24.00030 PMID: 38820503
pubmed: 38820503
doi: 10.1200/PO.24.00030
doi:

Substances chimiques

Proto-Oncogene Proteins B-raf EC 2.7.11.1
BRAF protein, human EC 2.7.11.1
Protein Kinase Inhibitors 0
Mitogen-Activated Protein Kinase Kinases EC 2.7.12.2

Types de publication

Journal Article Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2400030

Auteurs

Irina A Kerle (IA)

Department for Translational Medical Oncology, National Center for Tumor Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
Translational Medical Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
German Cancer Consortium (DKTK), Partner Site Dresden, Dresden, Germany.
ORCID: 0000-0002-3650-488X

Anne-Marie Scheuble (AM)

Department of Medicine 2, University Cancer Center Leipzig (UCCL), Leipzig University Medical Center, Cancer Center Central Germany (CCCG), Leipzig, Germany.

Benjamin Kobitzsch (B)

Department of Medicine 2, University Cancer Center Leipzig (UCCL), Leipzig University Medical Center, Cancer Center Central Germany (CCCG), Leipzig, Germany.
ORCID: 0000-0001-7327-2785

Gertraud Stocker (G)

Department of Medicine 2, University Cancer Center Leipzig (UCCL), Leipzig University Medical Center, Cancer Center Central Germany (CCCG), Leipzig, Germany.
ORCID: 0009-0002-5999-6351

G G Ruth Hiller (GGR)

Institute of Pathology, Leipzig University Medical Center, Leipzig, Germany.
ORCID: 0000-0002-6612-5178

Maja Badendick (M)

Department of Nuclear Medicine, Leipzig University Medical Center, Leipzig, Germany.

Doreen William (D)

German Cancer Consortium (DKTK), Partner Site Dresden, Dresden, Germany.
Core Unit for Molecular Tumor Diagnostics (CMTD), National Center for Tumor Diseases Dresden (NCT/UCC), Dresden, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.
Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
Institute for Clinical Genetics, University Hospital Carl Gustav Carus at TU Dresden, Dresden, Germany.
ERN GENTURIS, Hereditary Cancer Syndrome Center Dresden, Dresden, Germany.
ORCID: 0000-0001-7824-5073

Alexander Krueger (A)

German Cancer Consortium (DKTK), Partner Site Dresden, Dresden, Germany.
Core Unit for Molecular Tumor Diagnostics (CMTD), National Center for Tumor Diseases Dresden (NCT/UCC), Dresden, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.
Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
ORCID: 0000-0002-9878-1137

Thomas Gross (T)

German Cancer Consortium (DKTK), Partner Site Dresden, Dresden, Germany.
Core Unit for Molecular Tumor Diagnostics (CMTD), National Center for Tumor Diseases Dresden (NCT/UCC), Dresden, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.
Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.

Anja Koegler (A)

German Cancer Consortium (DKTK), Partner Site Dresden, Dresden, Germany.
Core Unit for Molecular Tumor Diagnostics (CMTD), National Center for Tumor Diseases Dresden (NCT/UCC), Dresden, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.
Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
ORCID: 0000-0003-4270-4762

Andreas Hartig (A)

Institute of Pathology, Carl Gustav Carus University Hospital, Dresden, Germany.

Daniela Richter (D)

Department for Translational Medical Oncology, National Center for Tumor Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
Translational Medical Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
German Cancer Research Center (DKFZ) Heidelberg, Translational Functional Cancer Genomics, Heidelberg, Germany.

Daniela E Aust (DE)

Institute of Pathology, Carl Gustav Carus University Hospital, Dresden, Germany.
ORCID: 0000-0002-4867-8852

Evelin Schroeck (E)

German Cancer Consortium (DKTK), Partner Site Dresden, Dresden, Germany.
Core Unit for Molecular Tumor Diagnostics (CMTD), National Center for Tumor Diseases Dresden (NCT/UCC), Dresden, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.
Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
Institute for Clinical Genetics, University Hospital Carl Gustav Carus at TU Dresden, Dresden, Germany.
ERN GENTURIS, Hereditary Cancer Syndrome Center Dresden, Dresden, Germany.

Christoph Heining (C)

Department for Translational Medical Oncology, National Center for Tumor Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
Translational Medical Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
German Cancer Consortium (DKTK), Partner Site Dresden, Dresden, Germany.

Hanno Glimm (H)

Department for Translational Medical Oncology, National Center for Tumor Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
Translational Medical Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
German Cancer Consortium (DKTK), Partner Site Dresden, Dresden, Germany.
German Cancer Research Center (DKFZ) Heidelberg, Translational Functional Cancer Genomics, Heidelberg, Germany.
ORCID: 0000-0003-4104-1135

Ulrich T Hacker (UT)

Department of Medicine 2, University Cancer Center Leipzig (UCCL), Leipzig University Medical Center, Cancer Center Central Germany (CCCG), Leipzig, Germany.
ORCID: 0000-0002-3253-8206

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Kinases raf › Protéines proto-oncogènes B-raf › Exceptional Response of
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Exceptional Response of
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › Exceptional Response of
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Exceptional Response of
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Exceptional Response of
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-tyrosine kinases › Mitogen-Activated Protein Kinase Kinases › Exceptional Response of